Background/Objectives: Hypertriglyceridaemia and systemic inflammation are prevalent in patients with schizophrenia and contribute to an increased risk of cardiovascular disease. Although elevated triglycerides (TGs) and remnant cholesterol are linked to inflammation in the general population and individuals with metabolic syndrome, whether they are associated in patients with schizophrenia remains unclear. Methods: Fasting levels of TG, cholesterol (total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and remnant cholesterol)), and markers of systemic inflammation including high-sensitivity C-reactive protein (hsCRP), leukocyte counts and their differentials (neutrophils, monocytes and lymphocytes) were determined in 147 patients diagnosed with schizophrenia on long-term antipsychotic regimens and compared with 56 age- and sex-matched healthy controls. Apolipoprotein B and glycosylation of acute phase reactant (GlycA) signatures were assessed by NMR. Circulating cytokine levels were measured by a cytokine/chemokine multiplex assay. Results: Patients with schizophrenia had markedly elevated TG and remnant cholesterol relative to controls and had evidence of systemic inflammation with increased circulating hsCRP, GlycA, leukocyte, neutrophil counts and neutrophil-to-lymphocyte ratio (NLR). Unexpectedly TG and remnant cholesterol did not correlate with systemic inflammatory markers in patients with schizophrenia, and differences in inflammatory markers between controls and patients persisted after adjusting for the lipid profile. Interleukin (IL)-10 levels were increased in patients with schizophrenia, suggesting an anti-inflammatory signature. Conclusions: The discordance between TG, remnant cholesterol and systemic inflammation in patients with schizophrenia suggests these are likely independent contributors to cardiovascular risk in this population.

Background: Myocarditis is a serious disease that has drawn increasing attention due to its association with COVID-19 and vaccination. This study investigates the epidemiology of myocarditis beyond the COVID-19 pandemic, including its incidence and outcomes over time. Methods: We analyzed the population-wide retrospective data from the Admitted-Patient-Data-Collection database of patients admitted to hospitals in New South Wales (NSW), Australia, with a diagnosis of myocarditis from 2001 to 2022. The incidence of myocarditis, changing classification of myocarditis over time, and complications of myocarditis over time were all calculated. Results: There were 4071 patients diagnosed with their first episode of myocarditis, with a median age of 42 years old, and 66% were male. The incidence of myocarditis in NSW has tripled over 20-years to 8.3 per-100,000-persons by 2022. Reactive myocarditis (i.e., myocarditis within 30-days of a respiratory or digestive illness) accounted for 38% of first presentations of myocarditis. Post COVID-19 myocarditis, a subset of reactive myocarditis, accounted for 42% of myocarditis admissions since the onset of the COVID-19 pandemic in Australia. Eight percent of patients had a background history of malignancy, and 6% had a history of autoimmune disease. In-hospital mortality was 4.5% during the entire study period but has been falling by 11% per year. During follow up, most readmissions for myocarditis occurred within 6-months; with 5.1% recurrence at 6-months compared to only 6.7% at 5-years. Conclusions: Myocarditis is an important condition with increasing incidence in Australia and with markedly changing characteristics in the pandemic and post pandemic era.

Background: Myocarditis is a life-threatening condition with an increasing incidence in the past two decades. Little is known about the frequency of specific causes of death following myocarditis. This study aimed to identify the different causes of death after myocarditis diagnosis and determine factors associated with mortality. Methods: We conducted a retrospective population-wide observational study in New South Wales (NSW), Australia from July 2004 to September 2021. Data were attained from the NSW Admitted Patient Data Collection database and death was tracked from the death registry to 31 March 2022. Cause of death was ascertained from manual reviews of all death certificates and adjudicated independently by three reviewers. Results: Among 4071 unique index admissions for myocarditis (median age: 42 years; 66% male), cumulative all-cause mortality was 4.5% in-hospital, 8.2% at 1 year, 13.3% at 5 years and 15.5% by the end of follow up (median 5.3 years). Within 30 days of admission, the leading cause of death was cardiovascular (66%), including myocarditis (36%) and heart failure (12%). Non cardiovascular causes accounted for 32% of deaths and included infection (17%) and malignancy (6%). Beyond 30 days, cardiovascular deaths declined to 34% (only 3% due to myocarditis). Higher mortality risk was associated with older age, higher Charlson comorbidity index, and myocarditis complicated by intensive care unit admission, heart failure, stroke, or arrhythmia. Conclusions: Patients admitted with myocarditis face significant mortality risks. The highest mortality occurs within the first 30 days, predominantly due to cardiovascular causes, although after 30 days the predominant cause of death shifts to non-cardiovascular causes.